ArticleFrontiers in oncology2023

Preclinical investigations of the efficacy of the glutaminase inhibitor CB-839 alone and in combinations in chronic lymphocytic leukemia.

Natalia Timofeeva et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.